Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
نویسندگان
چکیده
منابع مشابه
Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
Aims Paliperidone palmitate 3-month (PP3M) represents a new long-acting injectable antipsychotic therapeutic option. This review aims: 1) to summarize available data relating to efficacy, safety, tolerability and costs of PP3M; 2) to describe hospitalization rate, occupational status, treatment preference, satisfaction, adherence and caregiver burden of patients with schizophrenia who participa...
متن کاملThe Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Long-acting injectable antipsychotics (LAIs) are among the most effective treatments in psychiatry, yet they remain underutilized in clinical practice. Although LAIs are typically used to maintain treatment adherence in patients with chronic schizophrenia, recent research has suggested that they may also provide an effective treatment strategy for patients with early-phase or first-episode dise...
متن کاملTreatment of Schizophrenia with Long-Acting Injectable Antipsychotics
Characteristics of schizophrenia typically include positive symptoms such as hallucinations or delusions, disorganized speech, negative symptoms such as a flat affect or poverty of speech, and impairments in cognition including attention, memory and executive functions. A diagnosis of schizophrenia is based on the presence of such symptoms, associated with social or occupational dysfunction [2]...
متن کاملPM411. Evaluation of Paliperidone Palmitate Long-Acting Injectable Therapy by Duration of Illness in Patients With Schizophrenia
s | 49 Improvements in PANSS scores following OL PP1M were similar in recent RIS/PALI (mean [SD] of -18.3 [17.96]) and no prior RIS/PALI (-21.1 [16.40]) subgroups at OL endpoint. Relapse-free rates during DB phase were comparable across recent RIS/PALI (PP3M: 89.7%; PP1M: 87.1%, 95% CI for difference: [-4.7; 10.0]) and no RIS/PALI subgroups (PP3M: 91.6%; PP1M: 90.8%, 95% CI for difference: [-4....
متن کاملMaintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval
BACKGROUND Several clinical studies have established the efficacy, safety, and tolerability of long-acting risperidone administered once every 2 weeks in patients with schizophrenia or schizoaffective disorder. This report evaluates preliminary efficacy, safety, tolerability, and pharmacokinetic data for a novel (once-monthly) administration of long-acting injectable risperidone 50 mg in patien...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Consortium Psychiatricum
سال: 2020
ISSN: 2713-2919,2712-7672
DOI: 10.17650/2712-7672-2020-1-2-53-62